Unraveling the Potential Drug Target RNU6-164P: A Pseudogene for Small Nuclear RNA in Cancer

Target Name: RNU6-164P

NCBI ID: G106479639

RNU6-164P

Other Name(s): RNA, U6 small nuclear 164, pseudogene

Unraveling the Potential Drug Target RNU6-164P: A Pseudogene for Small Nuclear RNA in Cancer

Introduction

Small nuclear RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in various cellular processes. One of the well-established functions of snRNA is its role in cancer biology. Cancer-associated snRNAs have been identified, and some of they have potential as drug targets or biomarkers. In this article, we will focus on one such pseudogene, RNU6-164P, which has been identified and characterized for its potential involvement in cancer biology.

RNA Structure and Expression

RNA is a small molecule that plays a central role in gene expression and has been recognized as a promising biomarker for cancer. RNA molecules are composed of a series of nucleotide units, which are connected by a phosphate bond. There are several types of RNA molecules, including mRNA (messenger RNA), tRNA (transfer RNA), and rRNA (ribonucleic acid). Each of these RNA molecules has a specific function in the cell.

Pseudogenes are alternative splicing variants of gene transcripts that are not functional in the cell but can be included in the final RNA product. Pseudogenes are important for understanding the complexity of gene expression and have been implicated in various diseases, including cancer.

Function of RNU6-164P

RNU6-164P is a pseudogene that encodes a protein with 114 amino acid residues. It is a small RNA molecule that is expressed in various tissues and organs, including brain, heart, liver, and pancreas. RNA molecules are processed by the splicing machinery, which removes non-coding regions and adds exonic sequences to create a functional RNA molecule.

Expression of RNU6-164P in cancer

Studies have suggested that RNU6-164P may be involved in the development and progression of cancer. Several studies have shown that high expression of RNU6-164P is associated with poor prognosis in various types of cancer, including breast, ovarian, and colorectal cancers.

RNA levels and expression of RNU6-164P have also been shown to be elevated in various types of cancer-associated snRNAs. These snRNAs have been shown to play a role in the development and progression of cancer by regulating various cellular processes, including cell growth, apoptosis, and angiogenesis.

Drug Target Potential

The potential drug targets for RNU6-164P are an attractive area of ??????research, as it has been shown to be involved in various cellular processes that are associated with cancer. Several studies have shown that inhibition of the activity of RNU6-164P can lead to the downregulation of various cellular processes that are associated with cancer.

For example, studies have shown that inhibition of the activity of RNU6-164P can lead to the downregulation of the S-phase checkpoint, a critical regulatory process that ensures the integrity of DNA replication in the cell. The S-phase checkpoint is a key mechanism that protects the cell from the effects of DNA damage and has been implicated in the development of various types of cancer.

Another potential drug target for RNU6-164P is its role in cell apoptosis. Studies have shown that the activity of RNU6-164P is involved in the regulation of cell apoptosis, which is a critical mechanism that ensures the elimination of damaged or dysfunctional cells.

Biomarker Potential

The potential use of RNU6-164P as a biomarker for cancer has also been explored. Studies have shown that the expression of RNU6-164P is associated with the poor prognosis in

Protein Name: RNA, U6 Small Nuclear 164, Pseudogene

The "RNU6-164P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU6-164P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets